- Global Pharma News & Resources

Asia Pacific Newborn Screening Market is expected to reach US$ 495.1 Million With CAGR of Approx 12.7% By 2026

Asia Pacific Newborn Screening Market Insights

Infants are most vulnerable to diseases such as polio, epilepsy, encephalitis, asthma, COPD and other respiratory diseases, diarrhea, leukemia, anemia, and other rare diseases that results in substantial economic burden.

Newborn screening refers to various tests that are performed during first few hours or days of an infant’s life. These tests have the potential of preventing severe health problems and death. According to the American Academy of Pediatrics: 2018, newborn screening and diagnosis are important to ensure that all babies who are deaf or hard of hearing are identified as soon as possible. Moreover, according to the same source, 1 to 3 out of every 1,000 babies born in the U.S. have hearing level outside the typical range. When these babies receive early intervention services, it makes a big difference in their communication and language development in the future.

Get Sample PDF Brochure with Impact of COVID19:

Asia Pacific newborn screening market size was valued at US$ 171.3 million in 2017, and is expected to exhibit a CAGR of 12.7% during the forecast period (2018-2026).

Figure 1. Asia Pacific Newborn Screening Market Value (US$ Mn) Analysis and Forecast and Absolute $ Opportunity

Source: Coherent Market Insights Analysis (2018)

Increasing government initiatives is expected to drive growth of the Asia Pacific newborn screening market

Increasing engagement programs by various government healthcare regulatory bodies for newborn screening and its deployment for wider population base are expected to drive growth of the market during the forecast period. For instance, in June 2014, PerkinElmer, a company engaged in the diagnostics, life science research, food, environmental and industrial testing area, entered into an exclusive collaboration with China’s National Health and Family Planning Commission (NHFPC) to implement a three-year training program for newborn screening.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

The National Maternal & Children Health Surveillance Office (NMCHSO) is working with PerkinElmer, to increase availability and adoption of newborn screening in China, particularly via expansion in more rural areas.

Moreover, technological advancements in tandem mass spectrometry, colorimetric analysis test, fluorescence analysis test, enzyme or liquid chromatography, and various immunological assays and other analysis and high adoption rate of newborn screening with new technology are factors that are expected to drive growth of the market. In October 2018, LifeCell International, India’s leading stem cell bank and mother & baby diagnostics company, launched RightStart, the world’s first Integrated DNA testing for newborn screening to detect over 50 medical conditions.

However, lack of improvement in healthcare infrastructure and trained professionals are major factors that are expected to hinder growth of the Asia Pacific newborn screening market. Newborn screening is still not widely adopted in Asia Pacific region and requires more development and awareness. Countries in Asia Pacific region have high population and less number of trained professionals. High population with low and middle-income level and poor quality health services are expected to hinder growth of the market.

Share your precise requirements @

Asia Pacific Newborn Screening Market- Country Analysis

On the basis of country, Asia Pacific newborn screening market is segmented into China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific.

China is expected to account for major market share due to innovative and new initiatives by government for implementing various newborn screening programs. Currently Congenital Hypothyroidism (CH) and Phenylketonuria (PKU) and hearing loss are included as national wide screening program in China, which is also mandatory for all newborn.

In addition, over 150 Newborn Screening (NBS) labs in China offer screening program for Congenital Adrenal Hyperplasia (CAH) and Glucose-6-Phosphate Dehydrogenase Deficiency (G-6-PDD), and about 11 million babies had been screened for CAH and G6PD in 2017.

India is expected to witness significant growth in the Asia Pacific newborn screening market, owing to high birth rate in this region. For instance, according to the World Health Organization (WHO) 2016, India’s total population was 1,324,171,000, which is second-largest in Asia Pacific countries after China. Newborn birth rate in India is around 34 births per second and 2,062 births per hour.

View Press Release For More Information @

Figure 2: Asia Pacific Newborn Screening Market Share (%), By Country

Source: Coherent Market Insights Analysis (2018)

Asia Pacific Newborn Screening Market- Competitive Landscape

Key players operating in the Asia Pacific newborn screening market include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.

Detailed Segmentation:

  • Asia Pacific Newborn Screening Market, By Product Type:
    • Hearing Screening Devices
    • Mass Spectrometer
    • Pulse Oximetry
    • Assay Kits and Reagents
  • Asia Pacific Newborn Screening Market, By Test Type:
    • Phenylketonuria (PKU)
    • Critical Congenital Heart Defect (CCHD)
    • Hearing Screening
    • Sickle Cell Disease
    • Maple Syrup Urine Disease (MSUD)
    • Thyroid Disorder
    • Biotinidase Deficiency (BTD)
    • Others
  • Asia Pacific Newborn Screening Market, By End User:
    • Hospitals
    • Maternity & Specialty Clinics
    • Diagnostic Centers
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 05-Feb-2021